<code id='BD57C91626'></code><style id='BD57C91626'></style>
    • <acronym id='BD57C91626'></acronym>
      <center id='BD57C91626'><center id='BD57C91626'><tfoot id='BD57C91626'></tfoot></center><abbr id='BD57C91626'><dir id='BD57C91626'><tfoot id='BD57C91626'></tfoot><noframes id='BD57C91626'>

    • <optgroup id='BD57C91626'><strike id='BD57C91626'><sup id='BD57C91626'></sup></strike><code id='BD57C91626'></code></optgroup>
        1. <b id='BD57C91626'><label id='BD57C91626'><select id='BD57C91626'><dt id='BD57C91626'><span id='BD57C91626'></span></dt></select></label></b><u id='BD57C91626'></u>
          <i id='BD57C91626'><strike id='BD57C91626'><tt id='BD57C91626'><pre id='BD57C91626'></pre></tt></strike></i>

          entertainment

          entertainment

          author:explore    Page View:11
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          AbbVie dramatically boosts its spending on lobbying
          AbbVie dramatically boosts its spending on lobbying

          ThepharmagiantAbbViespentnearly$4milliononlobbyinginthefirstthreemonthsof2022—nearlyamilliondollarsm

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          Microbiome research is starting to find links to chronic diseases

          AdobeWeneverwalkalone.Acrossthelandscapeofourbodies,trillionsofmicrobesaccompanyusonthejourneyoflife